SEC Form 4 · accession 0001193125-26-355663
REVELATION BIOSCIENCES, INC. · REVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Rolke
Officer — Chief Executive Officer · Director
Period of report
Aug 17, 2026
Accepted (ET)
Aug 18, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001810560
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 17, 2026 | A | 208,076 | $0.00 | A | 422,814 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.